177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry

177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry
Conditions: Neuroendocrine Tumors; Neuroendocrine Tumor Grade 1; Neuroendocrine Tumor Grade 2; Lutetium Lu 177 Dotatate; Radiotherapy Planning, Computer-Assisted

Interventions: Drug: Lutetium Lu 177 dotatate therapy

Sponsors: University of Iowa; Novartis

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

May 3, 2024Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments